Fludeoxyglucose F-18 for Glioblastoma

1
Effectiveness
1
Safety
UCLA / Jonsson Comprehensive Cancer Center, Los Angeles, CA
Glioblastoma
Fludeoxyglucose F-18 - Radiation
Eligibility
18+
All Sexes
Eligible conditions
Glioblastoma

Study Summary

This study is evaluating whether a new imaging technique may help doctors determine whether a new treatment is working for patients with glioblastoma.

See full description

Treatment Effectiveness

Effectiveness Estimate

1 of 3

Study Objectives

This trial is evaluating whether Fludeoxyglucose F-18 will improve 2 primary outcomes in patients with Glioblastoma. Measurement will happen over the course of One PET/CT 48 hours after start of therapy.

Hour 48
Changes in glucose uptake
Hour 48
Very early changes in tumor glucose uptake predictive for objective treatments response and survival assessed using RANO criteria

Trial Safety

Safety Estimate

1 of 3

Trial Design

2 Treatment Groups

Control
Treatment (FDG PET/CT)

This trial requires 50 total participants across 2 different treatment groups

This trial involves 2 different treatments. Fludeoxyglucose F-18 is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are not being studied for commercial purposes.

Treatment (FDG PET/CT)Patients undergo standard FDG PET/CT scan 6-8 weeks before start of chemotherapy and one additional FDG PET/CT scan within 48 hours of the start of chemotherapy.
ControlNo treatment in the control group
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Fludeoxyglucose F-18
2008
Completed Phase 2
~410
Positron Emission Tomography
2019
Completed Phase 2
~2950
Computed Tomography
2017
Completed Phase 2
~3460

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: from baseline up to 48 hours
This trial has the following approximate timeline: 3 weeks for initial screening, variable treatment timelines, and roughly from baseline up to 48 hours for reporting.

Closest Location

UCLA / Jonsson Comprehensive Cancer Center - Los Angeles, CA

Eligibility Criteria

This trial is for patients born any sex aged 18 and older. There are 2 eligibility criteria to participate in this trial as listed below.

Mark “yes” if the following statements are true for you:
I am writing to inform you that I intend to start therapy show original
Patients with histologically proven high grade glioma

Patient Q&A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the signs of glioblastoma?

Add answer

The signs of brain tumor are not specific. They can also present with nonspecific symptoms. Most of the signs and symptoms are due to tumor effects.

Unverified Answer

Can glioblastoma be cured?

Add answer

Given the degree to which glioblastomas develop from normal glial cells, the results of the current study suggest that no currently available therapies offer the possibility of cure. Further investigation into effective, targeted therapies for glioblastomas is needed.

Unverified Answer

What causes glioblastoma?

Add answer

There is a wide variety of factors. However, a consistent cause is the mutation or loss of function of p53. This protein ordinarily activates cell cycle inhibitors. However, when p53 is defective, these tumor suppressor genes are overactivated, and the cell is allowed to grow to tumor status. Although many mutations of p53 have been identified in GBM, the effects of each are difficult to predict.

Unverified Answer

What are common treatments for glioblastoma?

Add answer

A combination of radiation therapy and chemotherapy with temozolomide, in addition to surgery, has been used successfully in the treatment of GBMs, and has resulted in a 15-month survival rate of 20% for patients diagnosed with glioblastoma, comparable to results achieved by other centers.

Unverified Answer

What is glioblastoma?

Add answer

Glioblastoma arises in one part of the brain, primarily from astrocytes, and is a malignant brain tumor composed mostly by undifferentiated, highly malignant, multipotent, and rapidly dividing non-cycling cells. Glioblastoma usually arises in the 41st and 46th decades of life. It has a poor prognosis and the mean survival time after diagnosis is only 11 months. The 5-year overall survival rate is about 17%. Brain tumor is the most common primary tumor and accounts for more than half cases.

Unverified Answer

How many people get glioblastoma a year in the United States?

Add answer

Around 25,000 people are diagnosed with glioblastoma in the United States each year. Approximately 7,000 people will die each year from this tumor, compared with an annual survival rate of 15%. Although glioblastoma tumors occur almost exclusively in men older than 50 years of age, the median age at diagnosis is approximately 11 years of age.

Unverified Answer

Have there been other clinical trials involving fludeoxyglucose f-18?

Add answer

A study that included patients with glioblastoma with a median age of 42 (range 22-64) received F-18 FDG PET 2 weeks after radiotherapy. The findings indicated a higher rate of PFS and OS when patients were treated with and without the new anti-angiogenics.

Unverified Answer

What are the chances of developing glioblastoma?

Add answer

Although the frequency of glioblastomas among adults is high, only 10.5% to 11.8% of all glioblastomas are sporadic, and most are hereditary. The major predisposing genetic syndromes are hereditary diffuse and familial oligodendroglioma/astrocytoma, hereditary astrocytoma syndrome, and Li-Fraumeni syndrome. The risk for developing glioblastoma can be estimated by the presence of one of the listed hereditary conditions. The occurrence of specific genes on human chromosomes such as 10q may play a role in predisposing to glioblastoma tumors, and have some implication in its pathogenesis.

Unverified Answer

What are the latest developments in fludeoxyglucose f-18 for therapeutic use?

Add answer

FDG-PET should be included in the assessment of patients whose tumours show signs of metabolic activity on conventional imaging but are not biopsy- or surgical-proven as having malignancy.

Unverified Answer

Have there been any new discoveries for treating glioblastoma?

Add answer

There have been no big breakthroughs in glioblastoma treatment. In the past 3 years, our data show some improvement in glioblastoma treatment. The most important factor to be able to prolong survival is to develop new, more efficient therapeutic strategies.

Unverified Answer

What are the common side effects of fludeoxyglucose f-18?

Add answer

Our patient experienced several severe side-effects, which were different between the two radiologists. To minimize the side effects of FDG-PET, we recommend that patient should be fully and well informed about the side effects before the exam and that the radiologists should receive detailed and explicit instructions in all aspects of performing the study, particularly on patient comfort and communication.

Unverified Answer

How serious can glioblastoma be?

Add answer

Seriousness of glioblastoma depends on the anatomical extent of tumor. It appears that overall survival is worse in patients with a WHO grade of 3 or 4.

Unverified Answer
See if you qualify for this trial
Get access to this novel treatment for Glioblastoma by sharing your contact details with the study coordinator.